1JK Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Apellis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$38.50 |
| 52 Week High | US$87.50 |
| 52 Week Low | US$19.00 |
| Beta | 0.96 |
| 1 Month Change | -12.55% |
| 3 Month Change | -37.41% |
| 1 Year Change | -51.58% |
| 3 Year Change | -1.80% |
| 5 Year Change | n/a |
| Change since IPO | 75.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1JK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -1.6% | -0.9% |
| 1Y | -51.6% | -26.8% | 4.5% |
Return vs Industry: 1JK underperformed the German Biotechs industry which returned -26.8% over the past year.
Return vs Market: 1JK underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| 1JK volatility | |
|---|---|
| 1JK Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1JK's share price has been volatile over the past 3 months.
Volatility Over Time: 1JK's weekly volatility has decreased from 14% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 704 | Cedric Francois | www.apellis.com |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.
Apellis Pharmaceuticals, Inc. Fundamentals Summary
| 1JK fundamental statistics | |
|---|---|
| Market cap | €4.77b |
| Earnings (TTM) | -€385.60m |
| Revenue (TTM) | €484.29m |
10.1x
P/S Ratio-12.7x
P/E RatioIs 1JK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1JK income statement (TTM) | |
|---|---|
| Revenue | US$524.07m |
| Cost of Revenue | US$399.97m |
| Gross Profit | US$124.10m |
| Other Expenses | US$541.37m |
| Earnings | -US$417.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.44 |
| Gross Margin | 23.68% |
| Net Profit Margin | -79.62% |
| Debt/Equity Ratio | 34.9% |
How did 1JK perform over the long term?
See historical performance and comparison